Global Antirheumatics Pharmaceutical

Antirheumatics Pharmaceutical Comprehensive Study by Type (Non-Steroidal Anti-Inflammatory Drugs, Steroidal Anti-Inflammatory Drugs, Slow Acting Drug, Immunological Preparation), Application (Pharmaceutical Industry, Hospital and Clinic, Other), Components (Methotrexate, Leflunomide, Hydroxychloroquine, Sulfasalazine), Administration Type (Orally, Subcutaneously (SC), Intravenously (IV)), Distribution Channel (Medical Stores, Pharmaceuticals, Online, Others), Disorder Type (Rheumatoid Arthritis, Systemic Sclerosis, Vasculitis, Spondyloarthritis, Inflammatory Myositis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Others), Side Effects (Rash, Diarrhea, Nausea, Abdominal Pain, Others) Players and Region - Global Market Outlook to 2026

Antirheumatics Pharmaceutical Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Antirheumatics Pharmaceutical Market Scope?
Antirheumatic drugs are a category of otherwise unrelated drugs that are defined by their use in rheumatoid arthritis to slow the progression of the disease. The term is often used in contrast to a nonsteroidal anti-inflammatory drug that refers to agents that treat inflammation but not the underlying cause, and steroids that weaken the immune response but are not enough to slow the progression of the disease. Anti-inflammatory drugs include medications used to treat the symptoms of rheumatoid arthritis and which can change the course of the disease. The medications that help treat symptoms such as pain and inflammation are aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and steroids. Medications that slow the progression of rheumatoid arthritis and can help with pain, inflammation, and stiffness are known as disease-modifying drugs for rheumatoid arthritis (DMARDs).

The Antirheumatics Pharmaceutical market study is being classified by Type (Non-Steroidal Anti-Inflammatory Drugs, Steroidal Anti-Inflammatory Drugs, Slow Acting Drug and Immunological Preparation), by Application (Pharmaceutical Industry, Hospital and Clinic and Other) and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Antirheumatics Pharmaceutical market throughout the predicted period.

AbbVie Inc. (United States), Novartis AG (Switzerland), Merck & Co. (United States), Amgen (United States), Bristol-Myers Squibb (United States), Pfizer (United States), Roche Holding AG (Switzerland), Johnson & Johnson (United States), UCB S.A. (Belgium), Eli Lilly and Company (United States) and Celgene Corporation (United States) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Antirheumatics Pharmaceutical market by Type, Application and Region.

On the basis of geography, the market of Antirheumatics Pharmaceutical has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


Disease-modifying antirheumatic drugs (DMARDs) are a class of drugs indicated for the treatment of rheumatoid arthritis (RA) and many other autoimmune disorders. Due to the high complexity involved in the appropriate use of these agents, and monitoring for adverse effects, DMARDs shall be ideally prescribed by an appropriate specialist such as rheumatologist, gastroenterologist, or dermatologist. The prescribing provider shall be familiar with these agents, their indications, and adverse effects. All patients prescribed DMARDs need to be closely followed to monitor their effectiveness and side effects.

Influencing Market Trend
  • Increasing Healthcare Spending and Demand for Drug Therapy

Market Drivers
  • Growing Geriatric Population across the Globe
  • Increasing Cases of Arthritis and Various Autoimmune Disorders

Opportunities
  • Research & Development and Product Innovation
  • Potential Growth From Emerging Countries

Restraints
  • Stringent Government Rules and Regulation
  • Side Effects Due to Antirheumatics Drug

Challenges
  • Availability of Substitutes


Key Target Audience
Providers of Antirheumatics Pharmaceutical, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Non-Steroidal Anti-Inflammatory Drugs
  • Steroidal Anti-Inflammatory Drugs
  • Slow Acting Drug
  • Immunological Preparation
By Application
  • Pharmaceutical Industry
  • Hospital and Clinic
  • Other
By Components
  • Methotrexate
  • Leflunomide
  • Hydroxychloroquine
  • Sulfasalazine

By Administration Type
  • Orally
  • Subcutaneously (SC)
  • Intravenously (IV)

By Distribution Channel
  • Medical Stores
  • Pharmaceuticals
  • Online
  • Others

By Disorder Type
  • Rheumatoid Arthritis
  • Systemic Sclerosis
  • Vasculitis
  • Spondyloarthritis
  • Inflammatory Myositis
  • Inflammatory Bowel Disease
  • Systemic Lupus Erythematosus
  • Others

By Side Effects
  • Rash
  • Diarrhea
  • Nausea
  • Abdominal Pain
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population across the Globe
      • 3.2.2. Increasing Cases of Arthritis and Various Autoimmune Disorders
    • 3.3. Market Challenges
      • 3.3.1. Availability of Substitutes
    • 3.4. Market Trends
      • 3.4.1. Increasing Healthcare Spending and Demand for Drug Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antirheumatics Pharmaceutical, by Type, Application, Components, Administration Type, Distribution Channel, Disorder Type, Side Effects and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antirheumatics Pharmaceutical (Value)
      • 5.2.1. Global Antirheumatics Pharmaceutical by: Type (Value)
        • 5.2.1.1. Non-Steroidal Anti-Inflammatory Drugs
        • 5.2.1.2. Steroidal Anti-Inflammatory Drugs
        • 5.2.1.3. Slow Acting Drug
        • 5.2.1.4. Immunological Preparation
      • 5.2.2. Global Antirheumatics Pharmaceutical by: Application (Value)
        • 5.2.2.1. Pharmaceutical Industry
        • 5.2.2.2. Hospital and Clinic
        • 5.2.2.3. Other
      • 5.2.3. Global Antirheumatics Pharmaceutical by: Components (Value)
        • 5.2.3.1. Methotrexate
        • 5.2.3.2. Leflunomide
        • 5.2.3.3. Hydroxychloroquine
        • 5.2.3.4. Sulfasalazine
      • 5.2.4. Global Antirheumatics Pharmaceutical by: Administration Type (Value)
        • 5.2.4.1. Orally
        • 5.2.4.2. Subcutaneously (SC)
        • 5.2.4.3. Intravenously (IV)
      • 5.2.5. Global Antirheumatics Pharmaceutical by: Distribution Channel (Value)
        • 5.2.5.1. Medical Stores
        • 5.2.5.2. Pharmaceuticals
        • 5.2.5.3. Online
        • 5.2.5.4. Others
      • 5.2.6. Global Antirheumatics Pharmaceutical by: Disorder Type (Value)
        • 5.2.6.1. Rheumatoid Arthritis
        • 5.2.6.2. Systemic Sclerosis
        • 5.2.6.3. Vasculitis
        • 5.2.6.4. Spondyloarthritis
        • 5.2.6.5. Inflammatory Myositis
        • 5.2.6.6. Inflammatory Bowel Disease
        • 5.2.6.7. Systemic Lupus Erythematosus
        • 5.2.6.8. Others
      • 5.2.7. Global Antirheumatics Pharmaceutical by: Side Effects (Value)
        • 5.2.7.1. Rash
        • 5.2.7.2. Diarrhea
        • 5.2.7.3. Nausea
        • 5.2.7.4. Abdominal Pain
        • 5.2.7.5. Others
      • 5.2.8. Global Antirheumatics Pharmaceutical Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Taiwan
          • 5.2.8.2.6. Australia
          • 5.2.8.2.7. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
    • 5.3. Global Antirheumatics Pharmaceutical (Volume)
      • 5.3.1. Global Antirheumatics Pharmaceutical by: Type (Volume)
        • 5.3.1.1. Non-Steroidal Anti-Inflammatory Drugs
        • 5.3.1.2. Steroidal Anti-Inflammatory Drugs
        • 5.3.1.3. Slow Acting Drug
        • 5.3.1.4. Immunological Preparation
      • 5.3.2. Global Antirheumatics Pharmaceutical by: Application (Volume)
        • 5.3.2.1. Pharmaceutical Industry
        • 5.3.2.2. Hospital and Clinic
        • 5.3.2.3. Other
      • 5.3.3. Global Antirheumatics Pharmaceutical by: Components (Volume)
        • 5.3.3.1. Methotrexate
        • 5.3.3.2. Leflunomide
        • 5.3.3.3. Hydroxychloroquine
        • 5.3.3.4. Sulfasalazine
      • 5.3.4. Global Antirheumatics Pharmaceutical by: Administration Type (Volume)
        • 5.3.4.1. Orally
        • 5.3.4.2. Subcutaneously (SC)
        • 5.3.4.3. Intravenously (IV)
      • 5.3.5. Global Antirheumatics Pharmaceutical by: Distribution Channel (Volume)
        • 5.3.5.1. Medical Stores
        • 5.3.5.2. Pharmaceuticals
        • 5.3.5.3. Online
        • 5.3.5.4. Others
      • 5.3.6. Global Antirheumatics Pharmaceutical by: Disorder Type (Volume)
        • 5.3.6.1. Rheumatoid Arthritis
        • 5.3.6.2. Systemic Sclerosis
        • 5.3.6.3. Vasculitis
        • 5.3.6.4. Spondyloarthritis
        • 5.3.6.5. Inflammatory Myositis
        • 5.3.6.6. Inflammatory Bowel Disease
        • 5.3.6.7. Systemic Lupus Erythematosus
        • 5.3.6.8. Others
      • 5.3.7. Global Antirheumatics Pharmaceutical by: Side Effects (Volume)
        • 5.3.7.1. Rash
        • 5.3.7.2. Diarrhea
        • 5.3.7.3. Nausea
        • 5.3.7.4. Abdominal Pain
        • 5.3.7.5. Others
      • 5.3.8. Global Antirheumatics Pharmaceutical Region
        • 5.3.8.1. South America
          • 5.3.8.1.1. Brazil
          • 5.3.8.1.2. Argentina
          • 5.3.8.1.3. Rest of South America
        • 5.3.8.2. Asia Pacific
          • 5.3.8.2.1. China
          • 5.3.8.2.2. Japan
          • 5.3.8.2.3. India
          • 5.3.8.2.4. South Korea
          • 5.3.8.2.5. Taiwan
          • 5.3.8.2.6. Australia
          • 5.3.8.2.7. Rest of Asia-Pacific
        • 5.3.8.3. Europe
          • 5.3.8.3.1. Germany
          • 5.3.8.3.2. France
          • 5.3.8.3.3. Italy
          • 5.3.8.3.4. United Kingdom
          • 5.3.8.3.5. Netherlands
          • 5.3.8.3.6. Rest of Europe
        • 5.3.8.4. MEA
          • 5.3.8.4.1. Middle East
          • 5.3.8.4.2. Africa
        • 5.3.8.5. North America
          • 5.3.8.5.1. United States
          • 5.3.8.5.2. Canada
          • 5.3.8.5.3. Mexico
    • 5.4. Global Antirheumatics Pharmaceutical (Price)
      • 5.4.1. Global Antirheumatics Pharmaceutical by: Type (Price)
  • 6. Antirheumatics Pharmaceutical: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche Holding AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. UCB S.A. (Belgium)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Celgene Corporation (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Antirheumatics Pharmaceutical Sale, by Type, Application, Components, Administration Type, Distribution Channel, Disorder Type, Side Effects and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antirheumatics Pharmaceutical (Value)
      • 7.2.1. Global Antirheumatics Pharmaceutical by: Type (Value)
        • 7.2.1.1. Non-Steroidal Anti-Inflammatory Drugs
        • 7.2.1.2. Steroidal Anti-Inflammatory Drugs
        • 7.2.1.3. Slow Acting Drug
        • 7.2.1.4. Immunological Preparation
      • 7.2.2. Global Antirheumatics Pharmaceutical by: Application (Value)
        • 7.2.2.1. Pharmaceutical Industry
        • 7.2.2.2. Hospital and Clinic
        • 7.2.2.3. Other
      • 7.2.3. Global Antirheumatics Pharmaceutical by: Components (Value)
        • 7.2.3.1. Methotrexate
        • 7.2.3.2. Leflunomide
        • 7.2.3.3. Hydroxychloroquine
        • 7.2.3.4. Sulfasalazine
      • 7.2.4. Global Antirheumatics Pharmaceutical by: Administration Type (Value)
        • 7.2.4.1. Orally
        • 7.2.4.2. Subcutaneously (SC)
        • 7.2.4.3. Intravenously (IV)
      • 7.2.5. Global Antirheumatics Pharmaceutical by: Distribution Channel (Value)
        • 7.2.5.1. Medical Stores
        • 7.2.5.2. Pharmaceuticals
        • 7.2.5.3. Online
        • 7.2.5.4. Others
      • 7.2.6. Global Antirheumatics Pharmaceutical by: Disorder Type (Value)
        • 7.2.6.1. Rheumatoid Arthritis
        • 7.2.6.2. Systemic Sclerosis
        • 7.2.6.3. Vasculitis
        • 7.2.6.4. Spondyloarthritis
        • 7.2.6.5. Inflammatory Myositis
        • 7.2.6.6. Inflammatory Bowel Disease
        • 7.2.6.7. Systemic Lupus Erythematosus
        • 7.2.6.8. Others
      • 7.2.7. Global Antirheumatics Pharmaceutical by: Side Effects (Value)
        • 7.2.7.1. Rash
        • 7.2.7.2. Diarrhea
        • 7.2.7.3. Nausea
        • 7.2.7.4. Abdominal Pain
        • 7.2.7.5. Others
      • 7.2.8. Global Antirheumatics Pharmaceutical Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Taiwan
          • 7.2.8.2.6. Australia
          • 7.2.8.2.7. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
    • 7.3. Global Antirheumatics Pharmaceutical (Volume)
      • 7.3.1. Global Antirheumatics Pharmaceutical by: Type (Volume)
        • 7.3.1.1. Non-Steroidal Anti-Inflammatory Drugs
        • 7.3.1.2. Steroidal Anti-Inflammatory Drugs
        • 7.3.1.3. Slow Acting Drug
        • 7.3.1.4. Immunological Preparation
      • 7.3.2. Global Antirheumatics Pharmaceutical by: Application (Volume)
        • 7.3.2.1. Pharmaceutical Industry
        • 7.3.2.2. Hospital and Clinic
        • 7.3.2.3. Other
      • 7.3.3. Global Antirheumatics Pharmaceutical by: Components (Volume)
        • 7.3.3.1. Methotrexate
        • 7.3.3.2. Leflunomide
        • 7.3.3.3. Hydroxychloroquine
        • 7.3.3.4. Sulfasalazine
      • 7.3.4. Global Antirheumatics Pharmaceutical by: Administration Type (Volume)
        • 7.3.4.1. Orally
        • 7.3.4.2. Subcutaneously (SC)
        • 7.3.4.3. Intravenously (IV)
      • 7.3.5. Global Antirheumatics Pharmaceutical by: Distribution Channel (Volume)
        • 7.3.5.1. Medical Stores
        • 7.3.5.2. Pharmaceuticals
        • 7.3.5.3. Online
        • 7.3.5.4. Others
      • 7.3.6. Global Antirheumatics Pharmaceutical by: Disorder Type (Volume)
        • 7.3.6.1. Rheumatoid Arthritis
        • 7.3.6.2. Systemic Sclerosis
        • 7.3.6.3. Vasculitis
        • 7.3.6.4. Spondyloarthritis
        • 7.3.6.5. Inflammatory Myositis
        • 7.3.6.6. Inflammatory Bowel Disease
        • 7.3.6.7. Systemic Lupus Erythematosus
        • 7.3.6.8. Others
      • 7.3.7. Global Antirheumatics Pharmaceutical by: Side Effects (Volume)
        • 7.3.7.1. Rash
        • 7.3.7.2. Diarrhea
        • 7.3.7.3. Nausea
        • 7.3.7.4. Abdominal Pain
        • 7.3.7.5. Others
      • 7.3.8. Global Antirheumatics Pharmaceutical Region
        • 7.3.8.1. South America
          • 7.3.8.1.1. Brazil
          • 7.3.8.1.2. Argentina
          • 7.3.8.1.3. Rest of South America
        • 7.3.8.2. Asia Pacific
          • 7.3.8.2.1. China
          • 7.3.8.2.2. Japan
          • 7.3.8.2.3. India
          • 7.3.8.2.4. South Korea
          • 7.3.8.2.5. Taiwan
          • 7.3.8.2.6. Australia
          • 7.3.8.2.7. Rest of Asia-Pacific
        • 7.3.8.3. Europe
          • 7.3.8.3.1. Germany
          • 7.3.8.3.2. France
          • 7.3.8.3.3. Italy
          • 7.3.8.3.4. United Kingdom
          • 7.3.8.3.5. Netherlands
          • 7.3.8.3.6. Rest of Europe
        • 7.3.8.4. MEA
          • 7.3.8.4.1. Middle East
          • 7.3.8.4.2. Africa
        • 7.3.8.5. North America
          • 7.3.8.5.1. United States
          • 7.3.8.5.2. Canada
          • 7.3.8.5.3. Mexico
    • 7.4. Global Antirheumatics Pharmaceutical (Price)
      • 7.4.1. Global Antirheumatics Pharmaceutical by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antirheumatics Pharmaceutical: by Type(USD Million)
  • Table 2. Antirheumatics Pharmaceutical Non-Steroidal Anti-Inflammatory Drugs , by Region USD Million (2015-2020)
  • Table 3. Antirheumatics Pharmaceutical Steroidal Anti-Inflammatory Drugs , by Region USD Million (2015-2020)
  • Table 4. Antirheumatics Pharmaceutical Slow Acting Drug , by Region USD Million (2015-2020)
  • Table 5. Antirheumatics Pharmaceutical Immunological Preparation , by Region USD Million (2015-2020)
  • Table 6. Antirheumatics Pharmaceutical: by Application(USD Million)
  • Table 7. Antirheumatics Pharmaceutical Pharmaceutical Industry , by Region USD Million (2015-2020)
  • Table 8. Antirheumatics Pharmaceutical Hospital and Clinic , by Region USD Million (2015-2020)
  • Table 9. Antirheumatics Pharmaceutical Other , by Region USD Million (2015-2020)
  • Table 10. Antirheumatics Pharmaceutical: by Components(USD Million)
  • Table 11. Antirheumatics Pharmaceutical Methotrexate , by Region USD Million (2015-2020)
  • Table 12. Antirheumatics Pharmaceutical Leflunomide , by Region USD Million (2015-2020)
  • Table 13. Antirheumatics Pharmaceutical Hydroxychloroquine , by Region USD Million (2015-2020)
  • Table 14. Antirheumatics Pharmaceutical Sulfasalazine , by Region USD Million (2015-2020)
  • Table 15. Antirheumatics Pharmaceutical: by Administration Type(USD Million)
  • Table 16. Antirheumatics Pharmaceutical Orally , by Region USD Million (2015-2020)
  • Table 17. Antirheumatics Pharmaceutical Subcutaneously (SC) , by Region USD Million (2015-2020)
  • Table 18. Antirheumatics Pharmaceutical Intravenously (IV) , by Region USD Million (2015-2020)
  • Table 19. Antirheumatics Pharmaceutical: by Distribution Channel(USD Million)
  • Table 20. Antirheumatics Pharmaceutical Medical Stores , by Region USD Million (2015-2020)
  • Table 21. Antirheumatics Pharmaceutical Pharmaceuticals , by Region USD Million (2015-2020)
  • Table 22. Antirheumatics Pharmaceutical Online , by Region USD Million (2015-2020)
  • Table 23. Antirheumatics Pharmaceutical Others , by Region USD Million (2015-2020)
  • Table 24. Antirheumatics Pharmaceutical: by Disorder Type(USD Million)
  • Table 25. Antirheumatics Pharmaceutical Rheumatoid Arthritis , by Region USD Million (2015-2020)
  • Table 26. Antirheumatics Pharmaceutical Systemic Sclerosis , by Region USD Million (2015-2020)
  • Table 27. Antirheumatics Pharmaceutical Vasculitis , by Region USD Million (2015-2020)
  • Table 28. Antirheumatics Pharmaceutical Spondyloarthritis , by Region USD Million (2015-2020)
  • Table 29. Antirheumatics Pharmaceutical Inflammatory Myositis , by Region USD Million (2015-2020)
  • Table 30. Antirheumatics Pharmaceutical Inflammatory Bowel Disease , by Region USD Million (2015-2020)
  • Table 31. Antirheumatics Pharmaceutical Systemic Lupus Erythematosus , by Region USD Million (2015-2020)
  • Table 32. Antirheumatics Pharmaceutical Others , by Region USD Million (2015-2020)
  • Table 33. Antirheumatics Pharmaceutical: by Side Effects(USD Million)
  • Table 34. Antirheumatics Pharmaceutical Rash , by Region USD Million (2015-2020)
  • Table 35. Antirheumatics Pharmaceutical Diarrhea , by Region USD Million (2015-2020)
  • Table 36. Antirheumatics Pharmaceutical Nausea , by Region USD Million (2015-2020)
  • Table 37. Antirheumatics Pharmaceutical Abdominal Pain , by Region USD Million (2015-2020)
  • Table 38. Antirheumatics Pharmaceutical Others , by Region USD Million (2015-2020)
  • Table 39. South America Antirheumatics Pharmaceutical, by Country USD Million (2015-2020)
  • Table 40. South America Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 41. South America Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 42. South America Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 43. South America Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 44. South America Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 45. South America Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 46. South America Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 47. Brazil Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 48. Brazil Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 49. Brazil Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 50. Brazil Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 51. Brazil Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 52. Brazil Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 53. Brazil Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 54. Argentina Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 55. Argentina Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 56. Argentina Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 57. Argentina Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 58. Argentina Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 59. Argentina Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 60. Argentina Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 61. Rest of South America Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 62. Rest of South America Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 63. Rest of South America Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 64. Rest of South America Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 65. Rest of South America Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 66. Rest of South America Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 67. Rest of South America Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 68. Asia Pacific Antirheumatics Pharmaceutical, by Country USD Million (2015-2020)
  • Table 69. Asia Pacific Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 70. Asia Pacific Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 71. Asia Pacific Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 72. Asia Pacific Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 73. Asia Pacific Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 74. Asia Pacific Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 75. Asia Pacific Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 76. China Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 77. China Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 78. China Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 79. China Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 80. China Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 81. China Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 82. China Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 83. Japan Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 84. Japan Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 85. Japan Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 86. Japan Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 87. Japan Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 88. Japan Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 89. Japan Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 90. India Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 91. India Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 92. India Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 93. India Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 94. India Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 95. India Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 96. India Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 97. South Korea Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 98. South Korea Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 99. South Korea Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 100. South Korea Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 101. South Korea Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 102. South Korea Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 103. South Korea Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 104. Taiwan Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 105. Taiwan Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 106. Taiwan Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 107. Taiwan Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 108. Taiwan Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 109. Taiwan Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 110. Taiwan Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 111. Australia Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 112. Australia Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 113. Australia Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 114. Australia Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 115. Australia Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 116. Australia Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 117. Australia Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 118. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 119. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 120. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 121. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 122. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 123. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 124. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 125. Europe Antirheumatics Pharmaceutical, by Country USD Million (2015-2020)
  • Table 126. Europe Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 127. Europe Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 128. Europe Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 129. Europe Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 130. Europe Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 131. Europe Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 132. Europe Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 133. Germany Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 134. Germany Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 135. Germany Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 136. Germany Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 137. Germany Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 138. Germany Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 139. Germany Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 140. France Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 141. France Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 142. France Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 143. France Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 144. France Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 145. France Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 146. France Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 147. Italy Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 148. Italy Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 149. Italy Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 150. Italy Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 151. Italy Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 152. Italy Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 153. Italy Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 154. United Kingdom Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 155. United Kingdom Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 156. United Kingdom Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 157. United Kingdom Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 158. United Kingdom Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 159. United Kingdom Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 160. United Kingdom Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 161. Netherlands Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 162. Netherlands Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 163. Netherlands Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 164. Netherlands Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 165. Netherlands Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 166. Netherlands Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 167. Netherlands Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 168. Rest of Europe Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 169. Rest of Europe Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 170. Rest of Europe Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 171. Rest of Europe Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 172. Rest of Europe Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 173. Rest of Europe Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 174. Rest of Europe Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 175. MEA Antirheumatics Pharmaceutical, by Country USD Million (2015-2020)
  • Table 176. MEA Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 177. MEA Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 178. MEA Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 179. MEA Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 180. MEA Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 181. MEA Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 182. MEA Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 183. Middle East Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 184. Middle East Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 185. Middle East Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 186. Middle East Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 187. Middle East Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 188. Middle East Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 189. Middle East Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 190. Africa Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 191. Africa Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 192. Africa Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 193. Africa Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 194. Africa Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 195. Africa Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 196. Africa Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 197. North America Antirheumatics Pharmaceutical, by Country USD Million (2015-2020)
  • Table 198. North America Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 199. North America Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 200. North America Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 201. North America Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 202. North America Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 203. North America Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 204. North America Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 205. United States Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 206. United States Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 207. United States Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 208. United States Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 209. United States Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 210. United States Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 211. United States Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 212. Canada Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 213. Canada Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 214. Canada Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 215. Canada Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 216. Canada Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 217. Canada Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 218. Canada Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 219. Mexico Antirheumatics Pharmaceutical, by Type USD Million (2015-2020)
  • Table 220. Mexico Antirheumatics Pharmaceutical, by Application USD Million (2015-2020)
  • Table 221. Mexico Antirheumatics Pharmaceutical, by Components USD Million (2015-2020)
  • Table 222. Mexico Antirheumatics Pharmaceutical, by Administration Type USD Million (2015-2020)
  • Table 223. Mexico Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2015-2020)
  • Table 224. Mexico Antirheumatics Pharmaceutical, by Disorder Type USD Million (2015-2020)
  • Table 225. Mexico Antirheumatics Pharmaceutical, by Side Effects USD Million (2015-2020)
  • Table 226. Antirheumatics Pharmaceutical Sales: by Type(K Tons)
  • Table 227. Antirheumatics Pharmaceutical Sales Non-Steroidal Anti-Inflammatory Drugs , by Region K Tons (2015-2020)
  • Table 228. Antirheumatics Pharmaceutical Sales Steroidal Anti-Inflammatory Drugs , by Region K Tons (2015-2020)
  • Table 229. Antirheumatics Pharmaceutical Sales Slow Acting Drug , by Region K Tons (2015-2020)
  • Table 230. Antirheumatics Pharmaceutical Sales Immunological Preparation , by Region K Tons (2015-2020)
  • Table 231. Antirheumatics Pharmaceutical Sales: by Application(K Tons)
  • Table 232. Antirheumatics Pharmaceutical Sales Pharmaceutical Industry , by Region K Tons (2015-2020)
  • Table 233. Antirheumatics Pharmaceutical Sales Hospital and Clinic , by Region K Tons (2015-2020)
  • Table 234. Antirheumatics Pharmaceutical Sales Other , by Region K Tons (2015-2020)
  • Table 235. Antirheumatics Pharmaceutical Sales: by Components(K Tons)
  • Table 236. Antirheumatics Pharmaceutical Sales Methotrexate , by Region K Tons (2015-2020)
  • Table 237. Antirheumatics Pharmaceutical Sales Leflunomide , by Region K Tons (2015-2020)
  • Table 238. Antirheumatics Pharmaceutical Sales Hydroxychloroquine , by Region K Tons (2015-2020)
  • Table 239. Antirheumatics Pharmaceutical Sales Sulfasalazine , by Region K Tons (2015-2020)
  • Table 240. Antirheumatics Pharmaceutical Sales: by Administration Type(K Tons)
  • Table 241. Antirheumatics Pharmaceutical Sales Orally , by Region K Tons (2015-2020)
  • Table 242. Antirheumatics Pharmaceutical Sales Subcutaneously (SC) , by Region K Tons (2015-2020)
  • Table 243. Antirheumatics Pharmaceutical Sales Intravenously (IV) , by Region K Tons (2015-2020)
  • Table 244. Antirheumatics Pharmaceutical Sales: by Distribution Channel(K Tons)
  • Table 245. Antirheumatics Pharmaceutical Sales Medical Stores , by Region K Tons (2015-2020)
  • Table 246. Antirheumatics Pharmaceutical Sales Pharmaceuticals , by Region K Tons (2015-2020)
  • Table 247. Antirheumatics Pharmaceutical Sales Online , by Region K Tons (2015-2020)
  • Table 248. Antirheumatics Pharmaceutical Sales Others , by Region K Tons (2015-2020)
  • Table 249. Antirheumatics Pharmaceutical Sales: by Disorder Type(K Tons)
  • Table 250. Antirheumatics Pharmaceutical Sales Rheumatoid Arthritis , by Region K Tons (2015-2020)
  • Table 251. Antirheumatics Pharmaceutical Sales Systemic Sclerosis , by Region K Tons (2015-2020)
  • Table 252. Antirheumatics Pharmaceutical Sales Vasculitis , by Region K Tons (2015-2020)
  • Table 253. Antirheumatics Pharmaceutical Sales Spondyloarthritis , by Region K Tons (2015-2020)
  • Table 254. Antirheumatics Pharmaceutical Sales Inflammatory Myositis , by Region K Tons (2015-2020)
  • Table 255. Antirheumatics Pharmaceutical Sales Inflammatory Bowel Disease , by Region K Tons (2015-2020)
  • Table 256. Antirheumatics Pharmaceutical Sales Systemic Lupus Erythematosus , by Region K Tons (2015-2020)
  • Table 257. Antirheumatics Pharmaceutical Sales Others , by Region K Tons (2015-2020)
  • Table 258. Antirheumatics Pharmaceutical Sales: by Side Effects(K Tons)
  • Table 259. Antirheumatics Pharmaceutical Sales Rash , by Region K Tons (2015-2020)
  • Table 260. Antirheumatics Pharmaceutical Sales Diarrhea , by Region K Tons (2015-2020)
  • Table 261. Antirheumatics Pharmaceutical Sales Nausea , by Region K Tons (2015-2020)
  • Table 262. Antirheumatics Pharmaceutical Sales Abdominal Pain , by Region K Tons (2015-2020)
  • Table 263. Antirheumatics Pharmaceutical Sales Others , by Region K Tons (2015-2020)
  • Table 264. South America Antirheumatics Pharmaceutical Sales, by Country K Tons (2015-2020)
  • Table 265. South America Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 266. South America Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 267. South America Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 268. South America Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 269. South America Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 270. South America Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 271. South America Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 272. Brazil Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 273. Brazil Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 274. Brazil Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 275. Brazil Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 276. Brazil Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 277. Brazil Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 278. Brazil Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 279. Argentina Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 280. Argentina Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 281. Argentina Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 282. Argentina Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 283. Argentina Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 284. Argentina Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 285. Argentina Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 286. Rest of South America Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 287. Rest of South America Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 288. Rest of South America Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 289. Rest of South America Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 290. Rest of South America Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 291. Rest of South America Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 292. Rest of South America Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 293. Asia Pacific Antirheumatics Pharmaceutical Sales, by Country K Tons (2015-2020)
  • Table 294. Asia Pacific Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 295. Asia Pacific Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 296. Asia Pacific Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 297. Asia Pacific Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 298. Asia Pacific Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 299. Asia Pacific Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 300. Asia Pacific Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 301. China Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 302. China Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 303. China Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 304. China Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 305. China Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 306. China Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 307. China Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 308. Japan Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 309. Japan Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 310. Japan Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 311. Japan Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 312. Japan Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 313. Japan Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 314. Japan Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 315. India Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 316. India Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 317. India Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 318. India Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 319. India Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 320. India Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 321. India Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 322. South Korea Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 323. South Korea Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 324. South Korea Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 325. South Korea Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 326. South Korea Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 327. South Korea Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 328. South Korea Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 329. Taiwan Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 330. Taiwan Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 331. Taiwan Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 332. Taiwan Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 333. Taiwan Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 334. Taiwan Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 335. Taiwan Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 336. Australia Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 337. Australia Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 338. Australia Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 339. Australia Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 340. Australia Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 341. Australia Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 342. Australia Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 343. Rest of Asia-Pacific Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 344. Rest of Asia-Pacific Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 345. Rest of Asia-Pacific Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 346. Rest of Asia-Pacific Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 347. Rest of Asia-Pacific Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 348. Rest of Asia-Pacific Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 349. Rest of Asia-Pacific Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 350. Europe Antirheumatics Pharmaceutical Sales, by Country K Tons (2015-2020)
  • Table 351. Europe Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 352. Europe Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 353. Europe Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 354. Europe Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 355. Europe Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 356. Europe Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 357. Europe Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 358. Germany Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 359. Germany Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 360. Germany Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 361. Germany Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 362. Germany Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 363. Germany Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 364. Germany Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 365. France Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 366. France Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 367. France Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 368. France Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 369. France Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 370. France Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 371. France Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 372. Italy Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 373. Italy Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 374. Italy Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 375. Italy Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 376. Italy Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 377. Italy Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 378. Italy Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 379. United Kingdom Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 380. United Kingdom Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 381. United Kingdom Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 382. United Kingdom Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 383. United Kingdom Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 384. United Kingdom Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 385. United Kingdom Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 386. Netherlands Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 387. Netherlands Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 388. Netherlands Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 389. Netherlands Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 390. Netherlands Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 391. Netherlands Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 392. Netherlands Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 393. Rest of Europe Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 394. Rest of Europe Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 395. Rest of Europe Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 396. Rest of Europe Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 397. Rest of Europe Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 398. Rest of Europe Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 399. Rest of Europe Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 400. MEA Antirheumatics Pharmaceutical Sales, by Country K Tons (2015-2020)
  • Table 401. MEA Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 402. MEA Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 403. MEA Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 404. MEA Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 405. MEA Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 406. MEA Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 407. MEA Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 408. Middle East Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 409. Middle East Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 410. Middle East Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 411. Middle East Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 412. Middle East Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 413. Middle East Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 414. Middle East Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 415. Africa Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 416. Africa Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 417. Africa Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 418. Africa Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 419. Africa Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 420. Africa Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 421. Africa Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 422. North America Antirheumatics Pharmaceutical Sales, by Country K Tons (2015-2020)
  • Table 423. North America Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 424. North America Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 425. North America Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 426. North America Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 427. North America Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 428. North America Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 429. North America Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 430. United States Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 431. United States Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 432. United States Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 433. United States Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 434. United States Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 435. United States Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 436. United States Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 437. Canada Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 438. Canada Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 439. Canada Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 440. Canada Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 441. Canada Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 442. Canada Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 443. Canada Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 444. Mexico Antirheumatics Pharmaceutical Sales, by Type K Tons (2015-2020)
  • Table 445. Mexico Antirheumatics Pharmaceutical Sales, by Application K Tons (2015-2020)
  • Table 446. Mexico Antirheumatics Pharmaceutical Sales, by Components K Tons (2015-2020)
  • Table 447. Mexico Antirheumatics Pharmaceutical Sales, by Administration Type K Tons (2015-2020)
  • Table 448. Mexico Antirheumatics Pharmaceutical Sales, by Distribution Channel K Tons (2015-2020)
  • Table 449. Mexico Antirheumatics Pharmaceutical Sales, by Disorder Type K Tons (2015-2020)
  • Table 450. Mexico Antirheumatics Pharmaceutical Sales, by Side Effects K Tons (2015-2020)
  • Table 451. Antirheumatics Pharmaceutical: by Type(USD/Units)
  • Table 452. Company Basic Information, Sales Area and Its Competitors
  • Table 453. Company Basic Information, Sales Area and Its Competitors
  • Table 454. Company Basic Information, Sales Area and Its Competitors
  • Table 455. Company Basic Information, Sales Area and Its Competitors
  • Table 456. Company Basic Information, Sales Area and Its Competitors
  • Table 457. Company Basic Information, Sales Area and Its Competitors
  • Table 458. Company Basic Information, Sales Area and Its Competitors
  • Table 459. Company Basic Information, Sales Area and Its Competitors
  • Table 460. Company Basic Information, Sales Area and Its Competitors
  • Table 461. Company Basic Information, Sales Area and Its Competitors
  • Table 462. Company Basic Information, Sales Area and Its Competitors
  • Table 463. Antirheumatics Pharmaceutical: by Type(USD Million)
  • Table 464. Antirheumatics Pharmaceutical Non-Steroidal Anti-Inflammatory Drugs , by Region USD Million (2021-2026)
  • Table 465. Antirheumatics Pharmaceutical Steroidal Anti-Inflammatory Drugs , by Region USD Million (2021-2026)
  • Table 466. Antirheumatics Pharmaceutical Slow Acting Drug , by Region USD Million (2021-2026)
  • Table 467. Antirheumatics Pharmaceutical Immunological Preparation , by Region USD Million (2021-2026)
  • Table 468. Antirheumatics Pharmaceutical: by Application(USD Million)
  • Table 469. Antirheumatics Pharmaceutical Pharmaceutical Industry , by Region USD Million (2021-2026)
  • Table 470. Antirheumatics Pharmaceutical Hospital and Clinic , by Region USD Million (2021-2026)
  • Table 471. Antirheumatics Pharmaceutical Other , by Region USD Million (2021-2026)
  • Table 472. Antirheumatics Pharmaceutical: by Components(USD Million)
  • Table 473. Antirheumatics Pharmaceutical Methotrexate , by Region USD Million (2021-2026)
  • Table 474. Antirheumatics Pharmaceutical Leflunomide , by Region USD Million (2021-2026)
  • Table 475. Antirheumatics Pharmaceutical Hydroxychloroquine , by Region USD Million (2021-2026)
  • Table 476. Antirheumatics Pharmaceutical Sulfasalazine , by Region USD Million (2021-2026)
  • Table 477. Antirheumatics Pharmaceutical: by Administration Type(USD Million)
  • Table 478. Antirheumatics Pharmaceutical Orally , by Region USD Million (2021-2026)
  • Table 479. Antirheumatics Pharmaceutical Subcutaneously (SC) , by Region USD Million (2021-2026)
  • Table 480. Antirheumatics Pharmaceutical Intravenously (IV) , by Region USD Million (2021-2026)
  • Table 481. Antirheumatics Pharmaceutical: by Distribution Channel(USD Million)
  • Table 482. Antirheumatics Pharmaceutical Medical Stores , by Region USD Million (2021-2026)
  • Table 483. Antirheumatics Pharmaceutical Pharmaceuticals , by Region USD Million (2021-2026)
  • Table 484. Antirheumatics Pharmaceutical Online , by Region USD Million (2021-2026)
  • Table 485. Antirheumatics Pharmaceutical Others , by Region USD Million (2021-2026)
  • Table 486. Antirheumatics Pharmaceutical: by Disorder Type(USD Million)
  • Table 487. Antirheumatics Pharmaceutical Rheumatoid Arthritis , by Region USD Million (2021-2026)
  • Table 488. Antirheumatics Pharmaceutical Systemic Sclerosis , by Region USD Million (2021-2026)
  • Table 489. Antirheumatics Pharmaceutical Vasculitis , by Region USD Million (2021-2026)
  • Table 490. Antirheumatics Pharmaceutical Spondyloarthritis , by Region USD Million (2021-2026)
  • Table 491. Antirheumatics Pharmaceutical Inflammatory Myositis , by Region USD Million (2021-2026)
  • Table 492. Antirheumatics Pharmaceutical Inflammatory Bowel Disease , by Region USD Million (2021-2026)
  • Table 493. Antirheumatics Pharmaceutical Systemic Lupus Erythematosus , by Region USD Million (2021-2026)
  • Table 494. Antirheumatics Pharmaceutical Others , by Region USD Million (2021-2026)
  • Table 495. Antirheumatics Pharmaceutical: by Side Effects(USD Million)
  • Table 496. Antirheumatics Pharmaceutical Rash , by Region USD Million (2021-2026)
  • Table 497. Antirheumatics Pharmaceutical Diarrhea , by Region USD Million (2021-2026)
  • Table 498. Antirheumatics Pharmaceutical Nausea , by Region USD Million (2021-2026)
  • Table 499. Antirheumatics Pharmaceutical Abdominal Pain , by Region USD Million (2021-2026)
  • Table 500. Antirheumatics Pharmaceutical Others , by Region USD Million (2021-2026)
  • Table 501. South America Antirheumatics Pharmaceutical, by Country USD Million (2021-2026)
  • Table 502. South America Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 503. South America Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 504. South America Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 505. South America Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 506. South America Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 507. South America Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 508. South America Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 509. Brazil Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 510. Brazil Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 511. Brazil Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 512. Brazil Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 513. Brazil Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 514. Brazil Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 515. Brazil Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 516. Argentina Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 517. Argentina Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 518. Argentina Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 519. Argentina Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 520. Argentina Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 521. Argentina Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 522. Argentina Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 523. Rest of South America Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 524. Rest of South America Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 525. Rest of South America Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 526. Rest of South America Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 527. Rest of South America Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 528. Rest of South America Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 529. Rest of South America Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 530. Asia Pacific Antirheumatics Pharmaceutical, by Country USD Million (2021-2026)
  • Table 531. Asia Pacific Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 532. Asia Pacific Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 533. Asia Pacific Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 534. Asia Pacific Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 535. Asia Pacific Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 536. Asia Pacific Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 537. Asia Pacific Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 538. China Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 539. China Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 540. China Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 541. China Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 542. China Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 543. China Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 544. China Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 545. Japan Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 546. Japan Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 547. Japan Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 548. Japan Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 549. Japan Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 550. Japan Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 551. Japan Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 552. India Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 553. India Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 554. India Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 555. India Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 556. India Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 557. India Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 558. India Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 559. South Korea Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 560. South Korea Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 561. South Korea Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 562. South Korea Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 563. South Korea Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 564. South Korea Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 565. South Korea Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 566. Taiwan Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 567. Taiwan Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 568. Taiwan Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 569. Taiwan Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 570. Taiwan Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 571. Taiwan Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 572. Taiwan Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 573. Australia Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 574. Australia Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 575. Australia Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 576. Australia Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 577. Australia Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 578. Australia Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 579. Australia Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 580. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 581. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 582. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 583. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 584. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 585. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 586. Rest of Asia-Pacific Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 587. Europe Antirheumatics Pharmaceutical, by Country USD Million (2021-2026)
  • Table 588. Europe Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 589. Europe Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 590. Europe Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 591. Europe Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 592. Europe Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 593. Europe Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 594. Europe Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 595. Germany Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 596. Germany Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 597. Germany Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 598. Germany Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 599. Germany Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 600. Germany Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 601. Germany Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 602. France Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 603. France Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 604. France Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 605. France Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 606. France Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 607. France Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 608. France Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 609. Italy Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 610. Italy Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 611. Italy Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 612. Italy Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 613. Italy Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 614. Italy Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 615. Italy Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 616. United Kingdom Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 617. United Kingdom Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 618. United Kingdom Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 619. United Kingdom Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 620. United Kingdom Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 621. United Kingdom Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 622. United Kingdom Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 623. Netherlands Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 624. Netherlands Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 625. Netherlands Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 626. Netherlands Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 627. Netherlands Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 628. Netherlands Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 629. Netherlands Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 630. Rest of Europe Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 631. Rest of Europe Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 632. Rest of Europe Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 633. Rest of Europe Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 634. Rest of Europe Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 635. Rest of Europe Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 636. Rest of Europe Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 637. MEA Antirheumatics Pharmaceutical, by Country USD Million (2021-2026)
  • Table 638. MEA Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 639. MEA Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 640. MEA Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 641. MEA Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 642. MEA Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 643. MEA Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 644. MEA Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 645. Middle East Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 646. Middle East Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 647. Middle East Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 648. Middle East Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
  • Table 649. Middle East Antirheumatics Pharmaceutical, by Distribution Channel USD Million (2021-2026)
  • Table 650. Middle East Antirheumatics Pharmaceutical, by Disorder Type USD Million (2021-2026)
  • Table 651. Middle East Antirheumatics Pharmaceutical, by Side Effects USD Million (2021-2026)
  • Table 652. Africa Antirheumatics Pharmaceutical, by Type USD Million (2021-2026)
  • Table 653. Africa Antirheumatics Pharmaceutical, by Application USD Million (2021-2026)
  • Table 654. Africa Antirheumatics Pharmaceutical, by Components USD Million (2021-2026)
  • Table 655. Africa Antirheumatics Pharmaceutical, by Administration Type USD Million (2021-2026)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antirheumatics Pharmaceutical: by Type USD Million (2015-2020)
  • Figure 5. Global Antirheumatics Pharmaceutical: by Application USD Million (2015-2020)
  • Figure 6. Global Antirheumatics Pharmaceutical: by Components USD Million (2015-2020)
  • Figure 7. Global Antirheumatics Pharmaceutical: by Administration Type USD Million (2015-2020)
  • Figure 8. Global Antirheumatics Pharmaceutical: by Distribution Channel USD Million (2015-2020)
  • Figure 9. Global Antirheumatics Pharmaceutical: by Disorder Type USD Million (2015-2020)
  • Figure 10. Global Antirheumatics Pharmaceutical: by Side Effects USD Million (2015-2020)
  • Figure 11. South America Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 12. Asia Pacific Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 13. Europe Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 14. MEA Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 15. North America Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 16. Global Antirheumatics Pharmaceutical: by Type K Tons (2015-2020)
  • Figure 17. Global Antirheumatics Pharmaceutical: by Application K Tons (2015-2020)
  • Figure 18. Global Antirheumatics Pharmaceutical: by Components K Tons (2015-2020)
  • Figure 19. Global Antirheumatics Pharmaceutical: by Administration Type K Tons (2015-2020)
  • Figure 20. Global Antirheumatics Pharmaceutical: by Distribution Channel K Tons (2015-2020)
  • Figure 21. Global Antirheumatics Pharmaceutical: by Disorder Type K Tons (2015-2020)
  • Figure 22. Global Antirheumatics Pharmaceutical: by Side Effects K Tons (2015-2020)
  • Figure 23. South America Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 24. Asia Pacific Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 25. Europe Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 26. MEA Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 27. North America Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 28. Global Antirheumatics Pharmaceutical: by Type USD/Units (2015-2020)
  • Figure 29. Global Antirheumatics Pharmaceutical share by Players 2020 (%)
  • Figure 30. Global Antirheumatics Pharmaceutical share by Players (Top 3) 2020(%)
  • Figure 31. Global Antirheumatics Pharmaceutical share by Players (Top 5) 2020(%)
  • Figure 32. BCG Matrix for key Companies
  • Figure 33. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 37. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 39. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 40. Amgen (United States) Revenue: by Geography 2020
  • Figure 41. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 42. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 43. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 44. Pfizer (United States) Revenue: by Geography 2020
  • Figure 45. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 46. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 47. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 48. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 49. UCB S.A. (Belgium) Revenue, Net Income and Gross profit
  • Figure 50. UCB S.A. (Belgium) Revenue: by Geography 2020
  • Figure 51. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 52. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 53. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 54. Celgene Corporation (United States) Revenue: by Geography 2020
  • Figure 55. Global Antirheumatics Pharmaceutical: by Type USD Million (2021-2026)
  • Figure 56. Global Antirheumatics Pharmaceutical: by Application USD Million (2021-2026)
  • Figure 57. Global Antirheumatics Pharmaceutical: by Components USD Million (2021-2026)
  • Figure 58. Global Antirheumatics Pharmaceutical: by Administration Type USD Million (2021-2026)
  • Figure 59. Global Antirheumatics Pharmaceutical: by Distribution Channel USD Million (2021-2026)
  • Figure 60. Global Antirheumatics Pharmaceutical: by Disorder Type USD Million (2021-2026)
  • Figure 61. Global Antirheumatics Pharmaceutical: by Side Effects USD Million (2021-2026)
  • Figure 62. South America Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 63. Asia Pacific Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 64. Europe Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 65. MEA Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 66. North America Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 67. Global Antirheumatics Pharmaceutical: by Type K Tons (2021-2026)
  • Figure 68. Global Antirheumatics Pharmaceutical: by Application K Tons (2021-2026)
  • Figure 69. Global Antirheumatics Pharmaceutical: by Components K Tons (2021-2026)
  • Figure 70. Global Antirheumatics Pharmaceutical: by Administration Type K Tons (2021-2026)
  • Figure 71. Global Antirheumatics Pharmaceutical: by Distribution Channel K Tons (2021-2026)
  • Figure 72. Global Antirheumatics Pharmaceutical: by Disorder Type K Tons (2021-2026)
  • Figure 73. Global Antirheumatics Pharmaceutical: by Side Effects K Tons (2021-2026)
  • Figure 74. South America Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 75. Asia Pacific Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 76. Europe Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 77. MEA Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 78. North America Antirheumatics Pharmaceutical Share (%), by Country
  • Figure 79. Global Antirheumatics Pharmaceutical: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • AbbVie Inc. (United States)
  • Novartis AG (Switzerland)
  • Merck & Co. (United States)
  • Amgen (United States)
  • Bristol-Myers Squibb (United States)
  • Pfizer (United States)
  • Roche Holding AG (Switzerland)
  • Johnson & Johnson (United States)
  • UCB S.A. (Belgium)
  • Eli Lilly and Company (United States)
  • Celgene Corporation (United States)
Select User Access Type

Key Highlights of Report


Dec 2021 240 Pages 95 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antirheumatics Pharmaceutical Quantitative research analysis
Global Antirheumatics Pharmaceutical Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Antirheumatics Pharmaceutical market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Antirheumatics Pharmaceutical market are AbbVie Inc. (United States), Novartis AG (Switzerland), Merck & Co. (United States), Amgen (United States), Bristol-Myers Squibb (United States), Pfizer (United States), Roche Holding AG (Switzerland), Johnson & Johnson (United States), UCB S.A. (Belgium), Eli Lilly and Company (United States) and Celgene Corporation (United States), to name a few.
In this highly competitive & fast evolving Antirheumatics Pharmaceutical industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Antirheumatics Pharmaceutical Report?

Have a Query? Click Here

Other Related Reports

Bronchiectasis Drugs Comprehensive Study by Type (Antibiotics, Expectorants, Beta-Agonists, Inhaled Corticosteroids, Others), Indication (Cylindrical Bronchiectasis, Varicose Bronchiectasis, Cystic B...
$ 3450
Blepharitis Comprehensive Study by Type (Anterior Blepharitis, Posterior Blepharitis, Mixed Blepharitis), Application (Specialty centers, Hospitals, Others), Treatment (Eye cleansers, Artificial tear...
$ 3650
Biologics Fill and Finish Services Comprehensive Study by Type (Liquid, Lyophilized), Application (Preclinical, Clinical, Commercial), Organization Size (Small-sized, Mid -sized, Large / very large),...
$ 3750
Thyroid Disorder Comprehensive Study by Type (Hypothyroidism, Hyperthyroidism, Goiter, Thyroid nodules, Thyroid cancer), Treatment (Homeopathic Treatment, Ayurvedic Treatment, Other (Allelopathy)), E...
$ 3750
Alfuzosin Comprehensive Study by Type (5mg Tablets, 10mg Tablets), Application (Hospital, Drug store) Players and Region - Global Market Outlook to 2025
$ 3500
Mesalamine Comprehensive Study by Type (Capsule, Tablets, Rectal Enema), Application (Hospital, Pharmacies, Medical Stores), Mode of Administration (Oral, Rectal), Dosage (250 mg, 375 mg, 400 mg, 500...
$ 3350